250 related articles for article (PubMed ID: 7753792)
1. Mammary tumor suppression by transforming growth factor beta 1 transgene expression.
Pierce DF; Gorska AE; Chytil A; Meise KS; Page DL; Coffey RJ; Moses HL
Proc Natl Acad Sci U S A; 1995 May; 92(10):4254-8. PubMed ID: 7753792
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation.
Gorska AE; Jensen RA; Shyr Y; Aakre ME; Bhowmick NA; Moses HL
Am J Pathol; 2003 Oct; 163(4):1539-49. PubMed ID: 14507660
[TBL] [Abstract][Full Text] [Related]
3. TGF beta regulation of cell proliferation.
Moses HL; Arteaga CL; Alexandrow MG; Dagnino L; Kawabata M; Pierce DF; Serra R
Princess Takamatsu Symp; 1994; 24():250-63. PubMed ID: 8983080
[TBL] [Abstract][Full Text] [Related]
4. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.
Matsui Y; Halter SA; Holt JT; Hogan BL; Coffey RJ
Cell; 1990 Jun; 61(6):1147-55. PubMed ID: 2161707
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1.
Pierce DF; Johnson MD; Matsui Y; Robinson SD; Gold LI; Purchio AF; Daniel CW; Hogan BL; Moses HL
Genes Dev; 1993 Dec; 7(12A):2308-17. PubMed ID: 8253379
[TBL] [Abstract][Full Text] [Related]
6. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
[TBL] [Abstract][Full Text] [Related]
7. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
[TBL] [Abstract][Full Text] [Related]
8. Normal and neoplastic mammary gland growth in MMTV/TGF alpha transgenic mice.
Mizuno M; Yamamoto K; Sakamoto S; Mori T; Harigaya T; Nagasawa H
In Vivo; 1994; 8(3):263-70. PubMed ID: 7803702
[TBL] [Abstract][Full Text] [Related]
9. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
[TBL] [Abstract][Full Text] [Related]
10. Decreased tumor formation in 7,12-dimethylbenzanthracene-treated stromelysin-1 transgenic mice is associated with alterations in mammary epithelial cell apoptosis.
Witty JP; Lempka T; Coffey RJ; Matrisian LM
Cancer Res; 1995 Apr; 55(7):1401-6. PubMed ID: 7882342
[TBL] [Abstract][Full Text] [Related]
11. Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene.
Coffey RJ; Meise KS; Matsui Y; Hogan BL; Dempsey PJ; Halter SA
Cancer Res; 1994 Apr; 54(7):1678-83. PubMed ID: 8137281
[TBL] [Abstract][Full Text] [Related]
12. Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia.
Hoshino A; Yee CJ; Campbell M; Woltjer RL; Townsend RL; van der Meer R; Shyr Y; Holt JT; Moses HL; Jensen RA
Int J Biol Sci; 2007 Apr; 3(5):281-91. PubMed ID: 17505536
[TBL] [Abstract][Full Text] [Related]
13. Impairment of mammary lobular development induced by expression of TGFbeta1 under the control of WAP promoter does not suppress tumorigenesis in MMTV-infected transgenic mice.
Buggiano V; Schere-Levy C; Abe K; Vanzulli S; Piazzon I; Smith GH; Kordon EC
Int J Cancer; 2001 May; 92(4):568-76. PubMed ID: 11304693
[TBL] [Abstract][Full Text] [Related]
14. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
Daphna-Iken D; Shankar DB; Lawshé A; Ornitz DM; Shackleford GM; MacArthur CA
Oncogene; 1998 Nov; 17(21):2711-7. PubMed ID: 9840935
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
[TBL] [Abstract][Full Text] [Related]
16. Reducing mammary cancer risk through premature stem cell senescence.
Boulanger CA; Smith GH
Oncogene; 2001 Apr; 20(18):2264-72. PubMed ID: 11402321
[TBL] [Abstract][Full Text] [Related]
17. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis.
Gallahan D; Jhappan C; Robinson G; Hennighausen L; Sharp R; Kordon E; Callahan R; Merlino G; Smith GH
Cancer Res; 1996 Apr; 56(8):1775-85. PubMed ID: 8620493
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.
Sinn E; Muller W; Pattengale P; Tepler I; Wallace R; Leder P
Cell; 1987 May; 49(4):465-75. PubMed ID: 3032456
[TBL] [Abstract][Full Text] [Related]
19. Wnt5a suppresses tumor formation and redirects tumor phenotype in MMTV-Wnt1 tumors.
Easter SL; Mitchell EH; Baxley SE; Desmond R; Frost AR; Serra R
PLoS One; 2014; 9(11):e113247. PubMed ID: 25401739
[TBL] [Abstract][Full Text] [Related]
20. Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.
Mao SPH; Park M; Cabrera RM; Christin JR; Karagiannis GS; Oktay MH; Zaiss DMW; Abrams SI; Guo W; Condeelis JS; Kenny PA; Segall JE
Breast Cancer Res; 2018 Oct; 20(1):131. PubMed ID: 30367629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
